ACADIA Pharmaceuticals Inc. (ACAD)
NASDAQ: ACAD · Real-Time Price · USD
21.85
-0.52 (-2.32%)
Nov 4, 2025, 4:00 PM EST - Market closed
ACADIA Pharmaceuticals Revenue
ACADIA Pharmaceuticals had revenue of $264.57M in the quarter ending June 30, 2025, with 9.34% growth. This brings the company's revenue in the last twelve months to $1.02B, up 14.41% year-over-year. In the year 2024, ACADIA Pharmaceuticals had annual revenue of $957.80M with 31.85% growth.
Revenue (ttm)
$1.02B
Revenue Growth
+14.41%
P/S Ratio
3.58
Revenue / Employee
$1,557,928
Employees
654
Market Cap
3.69B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 957.80M | 231.36M | 31.85% |
| Dec 31, 2023 | 726.44M | 209.20M | 40.45% |
| Dec 31, 2022 | 517.24M | 33.09M | 6.83% |
| Dec 31, 2021 | 484.15M | 42.39M | 9.60% |
| Dec 31, 2020 | 441.76M | 102.68M | 30.28% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 56.50B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.11B |
ACAD News
- 7 days ago - Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences - Business Wire
- 13 days ago - Halper Sadeh LLC Encourages Acadia Pharmaceuticals Inc. Shareholders to Contact the Firm to Discuss Their Rights - Business Wire
- 20 days ago - Acadia Pharmaceuticals to Announce Third Quarter 2025 Financial Results on November 5, 2025 - Business Wire
- 4 weeks ago - ACADIA Pharmaceuticals: Nuplazid And Daybue Are Enough To Remain Bullish - Seeking Alpha
- 4 weeks ago - Acadia Pharmaceuticals Presents Clinical Data from Across Multiple Therapeutic Programs at the 2025 International Congress of Parkinson's Disease and Movement Disorders® - Business Wire
- 5 weeks ago - Acadia Pharma Faces Trial Setback As Prader-Willi Syndrome Trial Falls Short - Benzinga
- 5 weeks ago - Acadia Pharmaceuticals' rare disease therapy fails late-stage trial - Reuters
- 5 weeks ago - Acadia Pharmaceuticals Announces Phase 3 COMPASS PWS Trial of Intranasal Carbetocin (ACP-101) for Hyperphagia in Prader-Willi Syndrome Did Not Meet Primary Endpoint - Business Wire